FY2025 Earnings Estimate for Opus Genetics Issued By Wedbush

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at Wedbush lifted their FY2025 earnings per share estimates for shares of Opus Genetics in a note issued to investors on Wednesday, November 12th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($0.63) per share for the year, up from their prior forecast of ($0.64). Wedbush currently has a “Outperform” rating and a $8.00 price target on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. Wedbush also issued estimates for Opus Genetics’ Q4 2025 earnings at ($0.11) EPS, FY2026 earnings at ($0.43) EPS, FY2027 earnings at ($0.30) EPS, FY2028 earnings at ($0.12) EPS and FY2029 earnings at $0.07 EPS.

Opus Genetics (NASDAQ:IRD) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.02. The company had revenue of $3.08 million during the quarter, compared to the consensus estimate of $3.07 million. Opus Genetics had a negative return on equity of 384.33% and a negative net margin of 377.89%.

Several other research firms have also commented on IRD. Chardan Capital restated a “buy” rating and issued a $9.00 price target on shares of Opus Genetics in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Opus Genetics in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Opus Genetics from a “hold” rating to a “sell” rating in a report on Saturday. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.80.

Opus Genetics Trading Up 1.6%

NASDAQ IRD opened at $1.88 on Monday. The company has a debt-to-equity ratio of 0.06, a current ratio of 1.90 and a quick ratio of 1.90. The company has a market cap of $122.21 million, a P/E ratio of -0.98 and a beta of 0.16. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $2.37. The company has a 50-day moving average of $1.83 and a 200-day moving average of $1.33.

Institutional Investors Weigh In On Opus Genetics

A number of institutional investors have recently modified their holdings of IRD. Apollon Wealth Management LLC bought a new position in Opus Genetics in the 1st quarter worth approximately $28,000. Kestra Private Wealth Services LLC acquired a new stake in shares of Opus Genetics during the 1st quarter valued at about $47,000. Virtu Financial LLC bought a new stake in shares of Opus Genetics in the 1st quarter valued at approximately $26,000. Voss Capital LP acquired a new position in Opus Genetics during the first quarter worth $147,000. Finally, Mink Brook Asset Management LLC bought a new stake in Opus Genetics during the first quarter worth about $795,000. Institutional investors and hedge funds own 14.97% of the company’s stock.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.